Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	129.42	99.6	83.57	72.05	67.45
Revenue Growth (YoY)	29.95%	19.18%	15.99%	6.82%	13.83%
Cost of Revenue	46.23	38.01	32.79	29.25	25.96
Gross Profit	83.19	61.59	50.78	42.8	41.49
Selling, General & Admin	62.56	47.84	51.42	56.6	64.73
Research & Development	6.33	6.02	4.96	4.83	3.83
Other Operating Expenses	1.98	-	-	-	-
Total Operating Expenses	70.88	53.86	56.38	61.43	68.56
Operating Income	12.31	7.73	-5.6	-18.63	-27.07
Interest Income	-	-	-	2.09	-
Other Non-Operating Income (Expense)	3.83	1.13	0.66	0	-0.06
Total Non-Operating Income (Expense)	3.83	1.13	0.66	2.09	-0.06
Pretax Income	16.14	8.86	-4.94	-16.54	-27.13
Provision for Income Taxes	0.81	0.31	0	-	-
Net Income	17.38	8.55	-4.94	-16.54	-27.13
Net Income to Common	17.38	8.55	-4.94	-16.54	-27.13
Net Income Growth	103.30%	-	-	-	-
Shares Outstanding (Basic)	79	76	75	70	67
Shares Outstanding (Diluted)	85	78	75	70	67
Shares Change (YoY)	9.36%	4.19%	7.54%	3.79%	10.02%
EPS (Basic)	0.22	0.11	-0.07	-0.24	-0.40
EPS (Diluted)	0.20	0.11	-0.07	-0.24	-0.40
EPS Growth	81.82%	-	-	-	-
Shares Outstanding	79.71	77.33	74.98	74.57	68.13
Free Cash Flow	13.21	11.95	6.97	-15.43	-24.57
Free Cash Flow Growth	10.60%	71.42%	-	-	-
Free Cash Flow Per Share	0.15	0.15	0.09	-0.22	-0.37
Gross Margin	64.28%	61.84%	60.76%	59.40%	61.51%
Operating Margin	9.51%	7.76%	-6.70%	-25.85%	-40.14%
Profit Margin	11.84%	8.58%	-5.91%	-22.96%	-40.22%
FCF Margin	10.21%	11.99%	8.34%	-21.42%	-36.43%
EBITDA	13.1	8.54	-4.57	-17.57	-25.96
EBITDA Margin	10.12%	8.57%	-5.47%	-24.39%	-38.49%
EBIT	12.31	7.73	-5.6	-18.63	-27.07
EBIT Margin	9.51%	7.76%	-6.70%	-25.85%	-40.14%
Effective Tax Rate	5.02%	3.44%	0.00%	0.00%	0.00%

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q